相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control
B. M. Van Maanen et al.
EXPERT REVIEW OF VACCINES (2017)
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study
Felix Weidemann et al.
BMC INFECTIOUS DISEASES (2017)
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
Bernhard Ultsch et al.
PHARMACOECONOMICS (2016)
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
P. Vemer et al.
PHARMACOECONOMICS (2016)
Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
Aurelien Jamotte et al.
BMC PUBLIC HEALTH (2016)
Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
George J. Milne et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2016)
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
Jiwon Lee et al.
NATURE MEDICINE (2016)
The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
Lisa Nagy et al.
PHARMACOECONOMICS (2016)
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
Pieter T. de Boer et al.
PHARMACOECONOMICS (2016)
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
Christiaan Dolk et al.
PHARMACOECONOMICS (2016)
Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?
Saverio Caini et al.
PLOS ONE (2016)
Influenza B vaccine lineage selection-An optimized trivalent vaccine
Ana Mosterin Hoepping et al.
VACCINE (2016)
Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States
Pieter T. de Boer et al.
VALUE IN HEALTH (2016)
A SYSTEMATIC REVIEW OF UTILITIY WEIGHTS FOR INFLUENZA AND INFLUENZA-LIKE ILLNESS
O. Damm et al.
VALUE IN HEALTH (2016)
Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
Mathieu Uhart et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain
Amos Garcia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries
Monica Tafalla et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines
Rahul Subramanian et al.
PLOS COMPUTATIONAL BIOLOGY (2016)
Estimating the Lineage Dynamics of Human Influenza B Viruses
Mayumbo Nyirenda et al.
PLOS ONE (2016)
Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom
Edward W. Thommes et al.
BMC INFECTIOUS DISEASES (2015)
Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014
A. Takla et al.
EUROSURVEILLANCE (2015)
Influenza B viruses: not to be discounted
Carolien E. van de Sandt et al.
FUTURE MICROBIOLOGY (2015)
Retrospective public health impact of a quadrivalent influenza vaccine in the United States
Pascal Crepey et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2015)
Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors
Ayman Chit et al.
VACCINE (2015)
Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis
Joyce H. S. You et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK
G. Meier et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
Thresholds for the cost-effectiveness of interventions: alternative approaches
Elliot Marseille et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2015)
Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type
Huong Q. McLean et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model
Ayman Chit et al.
PLOS ONE (2015)
Clinical Characteristics Are Similar across Type A and B Influenza Virus Infections
Anne Mosnier et al.
PLOS ONE (2015)
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head
Lidewij C. M. Wiersma et al.
VACCINES (2015)
A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly
Mark Mullikin et al.
INFECTIOUS DISEASES AND THERAPY (2015)
Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
Joyce H. S. You et al.
BMC INFECTIOUS DISEASES (2014)
4Flu-an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany
Martin Eichner et al.
BMC INFECTIOUS DISEASES (2014)
Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999-2012
Terho Heikkinen et al.
CLINICAL INFECTIOUS DISEASES (2014)
Influenza A/Subtype and B/Lineage Effectiveness Estimates for the 2011-2012 Trivalent Vaccine: Cross-Season and Cross-Lineage Protection With Unchanged Vaccine
Danuta M. Skowronski et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model
Laure-Anne Van Bellinghen et al.
PLOS ONE (2014)
Examining Ontario's universal influenza immunization program with a multi-strain dynamic model
E. W. Thommes et al.
VACCINE (2014)
Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination
Emma Quinn et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States
Karen M. Clements et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study
Andrew C. Hayward et al.
LANCET RESPIRATORY MEDICINE (2014)
Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis
Andrea C. Tricco et al.
BMC MEDICINE (2013)
Impact of Influenza on Health-Related Quality of Life among Confirmed (H1N1) 2009 Patients
Malen Hollmann et al.
PLOS ONE (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
PHARMACOECONOMICS (2013)
The economic value of a quadrivalent versus trivalent influenza vaccine (vol 30, pg 7443, 2012)
Bruce Y. Lee et al.
VACCINE (2013)
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5
Richard Pitman et al.
MEDICAL DECISION MAKING (2012)
Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials
Carlos A. DiazGranados et al.
VACCINE (2012)
Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine
Carrie Reed et al.
VACCINE (2012)
The rationale for quadrivalent influenza vaccines
Christopher S. Ambrose et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study
Albert Jan van Hoek et al.
PLOS ONE (2011)
Pharmacoeconomics: NICE's approach to decision-making
Michael Rawlins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Estimating the impact of childhood influenza vaccination programmes in England and Wales
Emilia Vynnycky et al.
VACCINE (2008)
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Noelle-Angelique M. Molinari et al.
VACCINE (2007)
分享论文
